Kesimpta outperforms Aubagio among ethnically diverse groups
Kesimpta (ofatumumab) is more effective than Aubagio (teriflunomide) among people with multiple sclerosis (MS) from ethnically diverse groups, including Black and African American, Hispanic and Latino, and Asian individuals, according to an analysis of pooled clinical trial data. āDetermining whether there are differences in how people respond…